Relay Therapeutics Financial Statements
NASDAQ: RLAYHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Relay Therapeutics revenue and earnings
In fiscal 2025, Relay Therapeutics generated $15.4 million in revenue, up 53.4% from fiscal 2024. Relay Therapeutics reported a net loss of $276.5 million, compared with a loss of $337.7 million a year earlier. Operating margin was -1971.6%.
Diluted earnings per share came in at -$1.61. Over the last 5 fiscal years, RLAY's revenue has grown at a -28.6% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Relay Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 15.36M | 10.01M | 25.55M | 1.38M | 3.03M | 82.65M | — |
| Revenue growth (YoY) | +53.44% | -60.83% | +1749.82% | -54.41% | -96.34% | — | — |
| Operating Expenses | 318.09M | 382.48M | 398.55M | 300.66M | 367.73M | 138.45M | 84.05M |
| Research & Development | 261.38M | 319.09M | 330.02M | 246.35M | 172.65M | 99.86M | 70.31M |
| Operating Income | -302.74M | -372.47M | -373.00M | -299.27M | -364.70M | -55.80M | -84.05M |
| Other Income (Expense) | 26.26M | 34.76M | 31.03M | 8.77M | 826.00K | 3.38M | 8.74M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -276.48M | -337.71M | -341.97M | -290.51M | -363.87M | -52.41M | -75.31M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | -5.40 | -21.82 |
| EPS (Diluted) | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | -5.40 | -21.82 |
| Shares Outstanding (Basic) | 171.59M | 142.87M | 122.58M | 112.23M | 95.14M | 42.62M | 3.45M |
| Shares Outstanding (Diluted) | — | — | — | 112.23M | 95.14M | 42.62M | 3.45M |
| EBITDA | -299.18M | -367.00M | -367.73M | -295.14M | -360.77M | -52.25M | -81.20M |
| Operating Margin | -1971.59% | -3722.07% | -1460.11% | -21670.89% | -12040.21% | -67.51% | — |
| Net Margin | -1800.58% | -3374.72% | -1338.66% | -21036.13% | -12012.94% | -63.41% | — |
This table shows 7 annual periods of Relay Therapeutics's income statement, from FY 2025 back to FY 2019, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow RLAY's reporting calendar. What is a income statement?